Education
About Us
Working with TipRanks
Follow Us
Gary Pace Insider Profile
25 Followers
Gary Pace, Director at Resmed, holds 2.11M shares in Cardiff Oncology (Ticker: CRDF), holds 22.13K shares in Pacira Pharmaceuticals (Ticker: PCRX), holds 100.58K shares in Resmed (Ticker: RMD). Most recently, Gary Pace Bought ― shares of Cardiff Oncology on Dec 12, 2024 for an estimated value of 940.20K.
Profitable Transactions
8 out of 20 Profitable Transactions
Average Return
+31.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Gary Pace holds in companies
Most Profitable Insider Trade
The most profitable trade made by Gary Pace
Gary Pace's Trading History
Resmed
May 10, 2018
Director
Uninformative Buy
783.35K
$23.38M
Cardiff Oncology
Dec 12, 2024
Director
Informative Buy
940.20K
$8.12M
Pacira Pharmaceuticals
Mar 08, 2024
Director
Informative Sell
3.66M
$517.11K
Imunon
―
Director
―
$39.24K
List of latest transactions for each holding click on a transaction to see Gary Pace's performance on stock
You May Also Like
Gary Pace insider profile FAQ
What is the percentage of profitable transactions made by Gary Pace?
The percentage of profitable transactions made by Gary Pace is 40%.
What is the average return per transaction made by Gary Pace?
The average return per transaction made by Gary Pace is 31.80%.
What stocks does Gary Pace hold?
Gary Pace holds: RMD, CRDF, PCRX, IMNN stocks.
What was Gary Pace’s latest transaction?
Gary Pace latest transaction was an Informative Buy of $940.20K.
What was Gary Pace's most profitable transaction?
Gary Pace’s most profitable transaction was an Informative Buy of CRDF stock on May 13, 2020. The return on the trade was 543.10%.
What is Gary Pace's role in Resmed?
Gary Pace's role in Resmed is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.